Theclinical application value ofFAM19A4/mir124-2 methylation test in hrHPV-positive women

Cervical cancer is one of the most common malignancies in women. The combination of human papillomavirus (HPV) genotyping with thinprep liquid-based cytology test (TCT) of cervical exfoliated cells and HPV vaccine helps greatly for the early diagnosis and prevention of cervical cancer. However, there is still a certain risk of missed diagnosis or over-diagnosis due to the limitations of its methodology. Therefore, women infected with high-risk HPV (hrHPV) need more reliable tests to identify whether the lesions will progress to cancer, which can guide early and accurate treatment and prevent over-treatment. Recently, studies have found that FAM19A4/mir124-2 methylation is closely related to cervical cancer, and its methylation degree increases with the severity of cervical lesions, which is expected to become a new biomarker of cervical cancer. Here, we summarized the clinical application value of FAM19A4/mir124-2 methylation test in hrHPV-positive women.